NCT05387512 2026-01-06
A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer
Affiliated Hospital of Nantong University
Completed
Clinical Trials
12 trialsNCT07266350 2025-12-05
A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer
Chongqing University Cancer Hospital
Not yet recruiting
NCT05713994 2025-03-25
CCGLC-001
Tongji Hospital
Recruiting
NCT06333561 2025-02-06
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
Sun Yat-sen University
Recruiting
NCT06485271 2024-07-03
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Changzhi People's Hospital Affiliated to Changzhi Medical College
Recruiting
NCT06376773 2024-04-19
Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.
Fujian Medical University
Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT06235164 2024-01-31
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Unknown
NCT04793139 2021-03-11
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
Guangdong Association of Clinical Trials
Unknown
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown
NCT04631146 2020-11-17
Efficacy and Safety of Camrelizumab in Real-World Study
Guangdong Association of Clinical Trials
Unknown
NCT04616040 2020-11-04
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
Peking University
Not yet recruiting